Logo image of VOR

VOR BIOPHARMA INC (VOR) Stock Price, Quote, News and Overview

NASDAQ:VOR - Nasdaq - US9290331084 - Common Stock - Currency: USD

0.1862  +0 (+1.92%)

VOR Quote, Performance and Key Statistics

VOR BIOPHARMA INC

NASDAQ:VOR (5/22/2025, 11:05:37 AM)

0.1862

+0 (+1.92%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.8
52 Week Low0.13
Market Cap23.25M
Shares124.85M
Float84.99M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO02-05 2021-02-05


VOR short term performance overview.The bars show the price performance of VOR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60 -80

VOR long term performance overview.The bars show the price performance of VOR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of VOR is 0.1862 USD. In the past month the price decreased by -75.93%. In the past year, price decreased by -88.25%.

VOR BIOPHARMA INC / VOR Daily stock chart

VOR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.6 319.83B
AMGN AMGEN INC 13.01 145.19B
GILD GILEAD SCIENCES INC 13.81 133.05B
VRTX VERTEX PHARMACEUTICALS INC N/A 110.92B
REGN REGENERON PHARMACEUTICALS 13.41 64.14B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.39B
ARGX ARGENX SE - ADR 98.98 35.48B
ONC BEIGENE LTD-ADR 5.95 25.82B
BNTX BIONTECH SE-ADR N/A 23.48B
NTRA NATERA INC N/A 20.80B
SMMT SUMMIT THERAPEUTICS INC N/A 19.03B
BIIB BIOGEN INC 7.95 18.42B

About VOR

Company Profile

VOR logo image Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidates include tremtelectogene empogeditemcel (trem-cel), for the treatment of acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II multicenter, open-label, first-in-human study of trem-cel in patients with AML. Its other clinical trial and pipeline products are VCAR33 / VBP301, Trem-cel+VCAR33 Treatment, System CD33-CLL1 Treatment System, and VADC45.

Company Info

VOR BIOPHARMA INC

100 Cambridgepark Drive, Suite 101

Cambridge MASSACHUSETTS US

Employees: 168

VOR Company Website

VOR Investor Relations

Phone: 16176556580

VOR BIOPHARMA INC / VOR FAQ

What is the stock price of VOR BIOPHARMA INC today?

The current stock price of VOR is 0.1862 USD. The price increased by 1.92% in the last trading session.


What is the ticker symbol for VOR BIOPHARMA INC stock?

The exchange symbol of VOR BIOPHARMA INC is VOR and it is listed on the Nasdaq exchange.


On which exchange is VOR stock listed?

VOR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VOR BIOPHARMA INC stock?

11 analysts have analysed VOR and the average price target is 9.03 USD. This implies a price increase of 4751.9% is expected in the next year compared to the current price of 0.1862. Check the VOR BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VOR BIOPHARMA INC worth?

VOR BIOPHARMA INC (VOR) has a market capitalization of 23.25M USD. This makes VOR a Nano Cap stock.


How many employees does VOR BIOPHARMA INC have?

VOR BIOPHARMA INC (VOR) currently has 168 employees.


What are the support and resistance levels for VOR BIOPHARMA INC (VOR) stock?

VOR BIOPHARMA INC (VOR) has a support level at 0.17. Check the full technical report for a detailed analysis of VOR support and resistance levels.


Should I buy VOR BIOPHARMA INC (VOR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VOR BIOPHARMA INC (VOR) stock pay dividends?

VOR does not pay a dividend.


When does VOR BIOPHARMA INC (VOR) report earnings?

VOR BIOPHARMA INC (VOR) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of VOR BIOPHARMA INC (VOR)?

VOR BIOPHARMA INC (VOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).


What is the Short Interest ratio of VOR BIOPHARMA INC (VOR) stock?

The outstanding short interest for VOR BIOPHARMA INC (VOR) is 1.3% of its float. Check the ownership tab for more information on the VOR short interest.


VOR Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

VOR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to VOR. While VOR seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VOR Financial Highlights

Over the last trailing twelve months VOR reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 7.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -81.82%
ROE -120.95%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%2.22%
Sales Q2Q%N/A
EPS 1Y (TTM)7.3%
Revenue 1Y (TTM)N/A

VOR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to VOR. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners49.54%
Ins Owners0.74%
Short Float %1.3%
Short Ratio1.34
Analysts
Analysts87.27
Price Target9.03 (4749.62%)
EPS Next Y60.76%
Revenue Next YearN/A